Investigational Drug Details
| Drug ID: | D253 |
| Drug Name: | Oleoylethanolamide |
| Synonyms: | N-(2-Hydroxyethyl)oleamide; N-OEA; N-oleoyl ethanolamine; N-oleoylethanolamine; OEA; Oleamide MEA; Oleoyl Ethanolamide; Oleoyl monoethanolamide; Oleoylethanolamide; Oleylethanolamide |
| Type: | Chemical drug |
| DrugBank ID: | DB16495 |
| DrugBank Description: | -- |
| PubChem ID: | 5283454 |
| CasNo: | 111-58-0 |
| Repositioning for NAFLD: | No |
| SMILES: | C(CCCCC/C=C\CCCCCCCC)CC(=O)NCCO |
| Structure: |
|
| InChiKey: | BOWVQLFMWHZBEF-KTKRTIGZSA-N |
| Molecular Weight: | 325.537 |
| DrugBank Targets: | -- |
| DrugBank MoA: | Oleoylethanolamide (OEA) is a major N-acylethanolamine and an endogenous ethanolamide fatty acid. Although it is an endocannabinoids-like compound, it does not bind to cannabinoid receptors. Instead, this lipid sensor is an agonist at peroxisome proliferator-activated receptor-α (PPAR-α) agonist while also being an inhibitor of ceramidase and thereby the sphingolipid signaling pathway. |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 3 on-going (IRCT20110530006652N2) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0490 | IRCT20090609002017N32 | Not applicable | Not Recruiting | No Results Available | 11/08/2018 | 26 May 2021 | Details |
| L0768 | IRCT20110530006652N2 | Phase 3 | Not Recruiting | No Results Available | 07/02/2019 | 18 May 2020 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A05283 | 33312933 | Health Promot Perspect | Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial. | Details |
| A07234 | 32572955 | J Cell Physiol | Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial. | Details |
| A08179 | 32217148 | Pharmacol Res | Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes. | Details |
| A10943 | 31111657 | Obes Rev | The effects of oleoylethanolamide, an endogenous PPAR-α agonist, on risk factors for NAFLD: A systematic review. | Details |
| A20643 | 25837920 | J Pharmacol Sci | Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats. | Details |